{"id":54713,"date":"2023-03-10T12:03:04","date_gmt":"2023-03-10T11:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/chimeric-antigen-receptor-macrophage-car-m-industry-landscape-analysis-report-2023-key-stakeholders-technologies-pipeline-partnering-and-financing-researchandmarkets-com\/"},"modified":"2023-03-10T12:03:04","modified_gmt":"2023-03-10T11:03:04","slug":"chimeric-antigen-receptor-macrophage-car-m-industry-landscape-analysis-report-2023-key-stakeholders-technologies-pipeline-partnering-and-financing-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/chimeric-antigen-receptor-macrophage-car-m-industry-landscape-analysis-report-2023-key-stakeholders-technologies-pipeline-partnering-and-financing-researchandmarkets-com\/","title":{"rendered":"Chimeric Antigen Receptor-Macrophage (CAR-M) Industry Landscape Analysis Report 2023: Key Stakeholders, Technologies, Pipeline, Partnering and Financing – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report provides you with a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023.\n<\/p>\n

\nCAR-M cell therapy is an approach to overcome the limitations and obstacles of CAR T-cell and CAR natural killer (NK) cell therapy. CAR macrophages bring several unique benefits. CAR macrophages can effortlessly submerge in the cancer environment.\n<\/p>\n

\nAdditionally, CAR-macrophages can decrease the ratio of tumor-associated macrophages (TAMs) and switch the phenotype of TAMs. Moreover, CAR macrophages play a phagocytic role in tumor cells, facilitate antigen presentation, and augment the cytotoxicity of T cells. Finally, CAR-macrophages have less toxicity and limited circulation time than T cells.\n<\/p>\n

\nResearch Methodology\/Scope<\/strong>\n<\/p>\n

\nThis report is based on information retrieved for CAR-M technology companies and partner companies regarding discovery and development collaborations, technology in- and out-licensing, and manufacturing arrangements. All information is fully referenced, either with scientific references (conference abstracts, Posters, presentations, full paper) or hyperlinks leading to the source of corporate information, such as press releases, corporate presentations, annual reports, SEC disclosures, and homepage content.\n<\/p>\n

\nDetails about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds, and sources are described in the company profiles. For each CAR-M technology company, a profile has been elaborated providing information about the company background\/history, the financial situation, relevant technology, partnering deals, and target & pipeline overview.\n<\/p>\n

\nA detailed description of CAR-M technologies from four companies is provided in the “CAR-M Technology Profiles” chapter. A general overview of CAR-M technologies from the other companies can be found in the respective company profile.\n<\/p>\n

\nEventually, this report has profiled seven CAR-M cell therapy candidates in the preclinical and clinical stages of R&D. The descriptions can be found in the chapter “CAR-M Cell Therapy Candidate Profiles” in alphabetical order by the drug code.\n<\/p>\n

\nA detailed CAR-M Industry Landscape Analysis precedes the three profile chapters with evaluations of the companies, CAR-M technologies, and the CAR-M pipeline with targets and information about preclinical and clinical experience.\n<\/p>\n

\nTwo main approaches for CAR-M cell therapy are:<\/strong>\n<\/p>\n